α1-Adrenergic receptor antagonist
Related Products
Labeled Version(s)
34999Alfuzosin-d7
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Alfuzosin (hydrochloride)

Item No. 13648

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furancarboxamide, monohydrochloride
CAS Number
81403-68-1
Synonyms
  • SL 77499-10
  • Uroxatral
Molecular Formula
C19H27N5O4 • HCl
Formula Weight
425.9
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMSO: 1 mg/mlEthanol: 1 mg/mlPBS (pH 7.2): 1 mg/ml
λmax
246, 331, 344 nm
SMILES
COC1=CC2=C(C(N)=NC(N(C)CCCNC(C3CCCO3)=O)=N2)C=C1OC.Cl
InChi Code
InChI=1S/C19H27N5O4.ClH/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19;/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23);1H
InChi Key
YTNKWDJILNVLGX-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $49

    Add

    10 mg

    $93

    Add

    25 mg

    $213

    Add

    50 mg

    $376

    Add
    Product Description

    Alfuzosin is a post-synaptic α1-adrenergic receptor antagonist commonly used to improve lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH).1,2 It displays high-affinity with non-selectivity for the three known human α1 adrenoceptors (pKi = 8.0, 8.0, and 8.5 for α1A, α1B, and α1D, respectively).3 Consistent with a role for α1 adrenoceptors in mediating contraction of smooth muscle, alfuzosin was first described as having anti-hypertensive effects with peripheral vasodilator properties.1 In patients with BPH, alfuzosin increases mean urinary flow rate and decreases residual volume.2 Alfuzosin produces minimal vasodilatory and sexual function side effects.4,5,6

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Sinclair, A.J., Davies, I.B., and Warrington, S.J. Alfuzosin and the venous reflex response: Studies in normal subjects. Br. J. Clin. Pharmacol. 27, 19-22 (1989).

    2. Jardin, A., Bensadoun, H., Delauche-Cavallier, M.C., et al. Alfuzosin for treatment of benign prostatic hypertrophy. Lancet 337, 1457-1461 (1991).

    3. Kenny, B.A., Miller, A.M., Williamson, I.J.R., et al. Evaluation of the pharmacological selectivity profile of α1 adrenoceptor antagonists at prostatic α1 adrenoceptors: Binding, functional and in vivo studies. Br. J. Pharmacol. 118(4), 871-878 (1996).

    4. Roehrborn, C.G., and Rosen, R.C. Medical therapy options for aging men with benign prostatic hyperplasia: Focus on alfuzosin 10 mg once daily. Clin. Interv. Aging 3(3), 511-524 (2008).

    5. Nickel, J.C., Sander, S., and Moon, T.D. A meta-analysis of the vascular-related safety profile and efficacy of α-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int. J. Clin. Pract. 62(10), 1547-1559 (2008).

    6. Michel, M.C. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: α-blockers in the treatment of male voiding dysfunction - how do they work and why do they differ in tolerability? J. Pharmacol. Sci. 112, 151-157 (2010).